VolitionRx - On the cusp of a breakthrough in testing for sepsis

(7:6)

VolitionRx on Commercial Launch of Cancer Screen Test for Canines and Veterinary Market Opportunity

(10:3)

Volition’s Nu.Q(TM) Vet Assay Detects Two Common Canine Cancers

(2:26)

VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

(3:42)

The Science Behind Our Work |

(4:46)

Webinar: Commercializing the Nu.Q® Vet Cancer Test.

(17:36)

VolitionRx Provides Update on Animal Health Blood Test Program, Licensing Deals and Focus for 2021

(10:16)

VolitionRx Breaks Down Supply Agreement of Nu.Q® Vet Cancer Tests with IDEXX Laboratories

(11:33)

Business Update and Dr Tom Butera Introduction

(11:50)

VolitionRx – Commercializing the Nu.Q Vet Cancer Test: Webinar

(36:37)

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

(1:1econd)

VolitionRx First Quarter 2024 Financial Results and Business Update

(8:32)

Volition Corporate Video - Oct 2024

(1:31)

Cameron Reynolds speaking about Volition's Assay Development Program

(1:40)

VolitionRx Limited Announces Interim Results from a 680-Subject Clinical Trial in Colorectal Cancer

(5:26)

Volition's Corporate Video

(3:36)

VolitionRX

(2:40)

VolitionRx Limited 2019 Full Year Earnings Results

(7:12)

Volition announces Strategic Acquisition

(3:36)

Cameron Reynolds, CEO - VolitionRx

(26:37)